Dr Hikmat Abdel-Razeq speaks to ecancer at the WIN 2019 Symposium in Paris about the use of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, metastatic breast cancer.

Dr Abdel-Razaq explains the issue of resistance when treated with conventional therapies such as aromatase inhibitors, however, the addition of CDK4/6 inhibitors seems to modulate the resistance, increased progression-free survival and provided an overall survival benefit - as shown in the MONALEESA-7 trial.

He also discusses the cost-effectiveness of these drugs and the potential use of these in other disease areas, such as non-small cell lung cancer (NSCLC).